Dapsone for Acute Ischemia Stroke Study (DAISY)

Cidat

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Stroke; Cerebrovascular Stroke; Stroke, Acute; Cerebrovascular Accident, Acute; Cerebral Stroke

Treatments: Drug: Dapsone; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01144650

CIDAT-072009-DAA-MC

Details and patient eligibility

About

The main purpose of the study is to get information about the safety and efficacy of treatment with Dapsone to prevent the disability after ischemic Stroke, in patients diagnosed with anterior territory brain infarct.

Full description

Cerebrovascular diseases are the third cause of mortality around the world. Seventy-five percent of the cases correspond to ischemic stroke, and the remaining 25 % to hemorrhagic infarct. The social impact of Stroke is high as it is the first cause for disabilities. After Stroke, several mechanisms of secondary damage act to spread the damage to the surrounding tissue. Those mechanisms include: 1) Excitotoxicity after excitatory amino acids' release 2) Overproduction of free radicals 3) Exacerbated inflammatory response and 4) Apoptosis. Many neuroprotective strategies have been tested to cope with the already mentioned damaging processes with poor clinical results. Many clinical trials have failed to provide neuroprotection to patients after acute stroke. Then, the need for safe drugs with clinical efficacy to prevent Stroke disability consequences is highly recognized. Dapsone is safe and relatively free of adverse reactions, we propose a clinical trial to assess the safety and efficacy of using this drug in patients with ischemic brain stroke.

Methods: A double-blind, placebo-controlled, randomized clinical trial of dapsone is to be conducted from 2009 to 2010. Three-hundred patients with a CT or MRI documented ischemic stroke in the anterior cerebral territory are to be included. Patients with 4 to 20 points of the National Institute of Health Stroke Scale (NIHSS) will be randomly allocated to receive either a single total dose of 250 mg dapsone or placebo within the first 12 h after stroke. For the follow-up, NIHSS on days 0, 2, 7, 30, 60 and 90, modified Rankin scale (mRS) on days 0, 30, 60 and 90, and Barthel index (BI) at day 90, will be all applied. Adverse reactions will be also recorded. The Primary clinical outcome of the patients will be assessed at 90 days after stroke by obtaining the shift analysis from the baseline levels of the scales mRS and NIHSS. Secondary clinical outcome will be the BI at day 90. An interim analysis of the data will be performed when the study have recruited one-hundred patients.

Statistical analysis will be performed with the intention-to-treat approach.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with the clinical diagnosis of an acute cerebrovascular event in in the anterior cerebral territory, within the last 12 hours who match the MRI or axial CT image.
• Patients with 4 o more points of the National Institute of Health Stroke Scale (NIHSS)
• Age older than 18 years, both gender
• Non acute cerebrovascular event previous
• Informed consent signed by patient or relatives

Exclusion criteria

• Diagnosed with recurrent diseases like: heart failure; Myocardial Infarction up 8 weeks before; ventrivular arrhythmia diagnosed by ECG; Second-Degree and Third-Degree Atrioventricular Block; or Long QT Syndrome.
• Pregnancy
• Allergic reactions to sulfa medications
• Patients with kidney failure and hepatic insufficiency
• Deficiency of glucose-6-phosphate dehydrogenase diagnosed

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

300 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Patients will receive either a single total dose of 250 mg placebo IV and oral dosage

Treatment:

Drug: Placebo

Dapsone

Experimental group

Description:

Patients will receive either a single total dose of 250 mg IV and oral dosage

Treatment:

Drug: Dapsone